Non-active antibiotic and bacteriophage synergism to successfully treat recurrent urinary tract infection caused by extensively drug-resistant Klebsiella pneumoniae

We report a case of a 63-year-old female patient who developed a recurrent urinary tract infection (UTI) with extensively drug-resistant Klebsiella pneumoniae (ERKp). In the initial two rounds of phage therapy, phage resistant mutants developed within days. Although ERKp strains were completely resi...

Full description

Saved in:
Bibliographic Details
Published in:Emerging microbes & infections 2020-01, Vol.9 (1), p.771-774
Main Authors: Bao, Juan, Wu, Nannan, Zeng, Yigang, Chen, Liguang, Li, Linlin, Yang, Lan, Zhang, Yiyuan, Guo, Mingquan, Li, Lisha, Li, Jie, Tan, Demeng, Cheng, Mengjun, Gu, Jingmin, Qin, Jinghong, Liu, Jiazheng, Li, Shiru, Pan, Guangqiang, Jin, Xin, Yao, Bangxin, Guo, Xiaokui, Zhu, Tongyu, Le, Shuai
Format: Article
Language:English
Subjects:
Anti-Bacterial Agents - therapeutic use
antibiotic resistance
Antibiotics
Bacteriophage
Drug resistance
Drug Resistance, Multiple, Bacterial
Female
Humans
Klebsiella Infections - therapy
Klebsiella pneumoniae
Letter
Microbial Sensitivity Tests
Middle Aged
Mutation
Phage Therapy
Recurrence
Urinary tract diseases
urinary tract infection
Urinary tract infections
Urinary Tract Infections - microbiology
Urinary Tract Infections - therapy
Urogenital system
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report a case of a 63-year-old female patient who developed a recurrent urinary tract infection (UTI) with extensively drug-resistant Klebsiella pneumoniae (ERKp). In the initial two rounds of phage therapy, phage resistant mutants developed within days. Although ERKp strains were completely resistant to sulfamethoxazole-trimethoprim, the combination of sulfamethoxazole-trimethoprim with the phage cocktail inhibited the emergence of phage resistant mutant in vitro, and the UTI of patient was successfully cured by this combination. Thus, we propose that non-active antibiotic and bacteriophage synergism (NABS) might be an alternative strategy in personalized phage therapy.
ISSN:2222-1751
2222-1751
DOI:10.1080/22221751.2020.1747950